RECIST stands for Response Evaluation Criteria in Solid Tumors. The National Cancer Institute is the best resource for information, and defines RECIST criteria as “a voluntary, international standard, and not an NCI standard. They are based on a simplification of former methods (WHO, ECOG) and based on measurable disease, i.e., the presence of at least one measurable lesion.” RECIST criteria provide a way to standardize measurement of solid tumors worldwide for any clinical trials that include this data to define study endpoints.
RECIST defines and standardizes how and when subjects are seen to progress, respond or remain stable in terms of their metastatic disease burden during a course of therapy. When these criteria are not well understood at the site level or consistently followed during a trial, it can put the study endpoint data in jeopardy.
2 окт 2017
